Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the disease. Here we describe the rationale and design of OCEAN (NCT03151811), a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melflufen + dexamethasone versus pomalidomide + dexamethasone. Eligible patients with relapsed refractory multiple myeloma have received 2-4 previous treatments and are refractory to both lenalidomide and their last treatment. Patients are excluded if they have previously received pomalidomide. The primary endpoint is progression-free survival, and key secondary endpoints include overall response rate, duration of response and overall survival.

Erasmus MC Cancer Institute and Erasmus University of Rotterdam Rotterdam The Netherlands

Medical University of Lodz Lodz Poland

Oncopeptides AB Stockholm Sweden

Oslo Myeloma Center Oslo University Hospital and KG Jebsen Center for B Cell Malignancies University of Oslo Oslo Norway

University Hospital of Masaryk Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc20028317

003      

CZ-PrNML

005      

20210114153518.0

007      

ta

008      

210105s2020 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.2217/fon-2020-0024 $2 doi

035    __

$a (PubMed)32141766

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Schjesvold, Fredrik $u Oslo Myeloma Center, Oslo University Hospital & KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.

245    10

$a OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma / $c F. Schjesvold, P. Robak, L. Pour, J. Aschan, P. Sonneveld,

520    9_

$a Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the disease. Here we describe the rationale and design of OCEAN (NCT03151811), a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melflufen + dexamethasone versus pomalidomide + dexamethasone. Eligible patients with relapsed refractory multiple myeloma have received 2-4 previous treatments and are refractory to both lenalidomide and their last treatment. Patients are excluded if they have previously received pomalidomide. The primary endpoint is progression-free survival, and key secondary endpoints include overall response rate, duration of response and overall survival.

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971

650    _2

$a klinické zkoušky, fáze III jako téma $7 D017326

650    _2

$a dexamethason $x terapeutické užití $7 D003907

650    _2

$a chemorezistence $7 D019008

650    _2

$a lidé $7 D006801

650    _2

$a lenalidomid $x škodlivé účinky $7 D000077269

650    _2

$a melfalan $x analogy a deriváty $x terapeutické užití $7 D008558

650    _2

$a mnohočetný myelom $x farmakoterapie $x patologie $7 D009101

650    _2

$a fenylalanin $x analogy a deriváty $x terapeutické užití $7 D010649

650    _2

$a doba přežití bez progrese choroby $7 D000077982

650    _2

$a randomizované kontrolované studie jako téma $7 D016032

650    _2

$a recidiva $7 D012008

650    _2

$a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792

655    _2

$a protokol klinické studie $7 D000078325

655    _2

$a časopisecké články $7 D016428

700    1_

$a Robak, Pawel $u Medical University of Lodz, Lodz, Poland.

700    1_

$a Pour, Ludek $u University Hospital of Masaryk, Brno, Czech Republic.

700    1_

$a Aschan, Johan $u Oncopeptides AB, Stockholm, Sweden.

700    1_

$a Sonneveld, Pieter $u Erasmus MC Cancer Institute & Erasmus University of Rotterdam, Rotterdam, The Netherlands.

773    0_

$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 16, č. 11 (2020), s. 631-641

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32141766 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20210105 $b ABA008

991    __

$a 20210114153515 $b ABA008

999    __

$a ok $b bmc $g 1608652 $s 1119497

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 16 $c 11 $d 631-641 $e 20200306 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687

LZP    __

$a Pubmed-20210105